Frontiers in oncology · 2026
Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schwörer Isabella, Huwer Sarah, Rautenberg Beate, Neubauer Jakob, Juhasz-Böss Ingolf, Jung Lisa
Аннотация
INTRODUCTION: Mirvetuximab-Soravtansin (MIRV) is an antibody-drug conjugate (ADC) for the therapy of advanced platinum-resistant folate receptor α (FRα)-expressing ovarian cancer. The goal of the study was to treat patients with MIRV off-label in our Comprehensive Cancer Center regarding the outcome and adverse events.
METHODS: This retrospective single-center cohort study included six patients with advanced high-grade serous ovarian cancer (HGSOC) or high-grade serous primary peritoneal carcinoma (PPC) with initial FIGO stage IIC-IV between July 2023 and August 2024. Inclusion criteria were metastatic advanced HGSOC or PPC, expression of FRα ≥75% (IHC PS2+), and progression during systemic therapy with ≥3 therapies before. All patients underwent ophthalmological examination before therapy with MIRV.
RESULTS: After 2-6 cycles of MIRV (median, 3.3), objective descriptive response with computed tomography (CT) scan of the thorax-abdomen and CA-125 response were monitored. CA-125 decreased in all evaluable patients (n, 5) from baseline. In the CT scan, two patients showed radiographically stable disease, and one of our patients represented progressive disease. Two patients revealed a partial response, and one of them had partial remission at the initial FIGO stage IV. Adverse events were monitored; one patient developed transient ocular toxicity.
DISCUSSION: Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.
METHODS: This retrospective single-center cohort study included six patients with advanced high-grade serous ovarian cancer (HGSOC) or high-grade serous primary peritoneal carcinoma (PPC) with initial FIGO stage IIC-IV between July 2023 and August 2024. Inclusion criteria were metastatic advanced HGSOC or PPC, expression of FRα ≥75% (IHC PS2+), and progression during systemic therapy with ≥3 therapies before. All patients underwent ophthalmological examination before therapy with MIRV.
RESULTS: After 2-6 cycles of MIRV (median, 3.3), objective descriptive response with computed tomography (CT) scan of the thorax-abdomen and CA-125 response were monitored. CA-125 decreased in all evaluable patients (n, 5) from baseline. In the CT scan, two patients showed radiographically stable disease, and one of our patients represented progressive disease. Two patients revealed a partial response, and one of them had partial remission at the initial FIGO stage IV. Adverse events were monitored; one patient developed transient ocular toxicity.
DISCUSSION: Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.